Esculentoside A inhibits ethyl alcohol-induced lipid accumulation and oxidative stress in hepatocytes by activating the AMPK pathway

Alcoholic fatty liver disease (AFLD) is a liver illness resulting from excessive alcohol consumption. Esculentoside A (EsA) possesses various properties, including antioxidative and anti-inflammatory capabilities, but its role and mechanism in AFLD have remained unclear. In this study, we aimed to elucidate the functions of EsA in AFLD. We utilized ethyl alcohol-induced Alpha Mouse 12 (AML-12) cells as a model to mimic AFLD conditions. Cell viability was evaluated utilizing the Cell Counting Kit-8 assay. Lipid accumulation was quantified via Oil Red O staining. The expression levels of key genes associated with lipid accumulation were determined using quantitative reverse transcriptase polymerase chain reaction (qRT-PCR), and the contents of triglycerides (TG), aspartate aminotransferase (AST), alanine aminotransferase (ALT), reactive oxygen species (ROS) and superoxide dismutase (SOD) activity were quantified using commercially available assay kits. Additionally, western blot was performed to determine the levels of p-AMP-activated protein kinase (AMPK) Thr172/AMPK and peroxisome proliferator-activated receptor-alpha (PPARα). Our findings demonstrate that EsA effectively mitigated the damage induced by ethanol (EtOH) in AML-12 cells. Notably, EsA exhibited significant inhibitory effects on EtOH-induced lipid accumulation and oxidative stress in AML-12 cells. Importantly, our data suggest a potential connection between EsA-mediated effects and the activation of the AMPK pathway in EtOH-induced damage to AML-12 cells. In conclusion, EsA demonstrates promise in attenuating ethyl alcohol-induced lipid accumulation and oxidative stress in hepatocytes, likely through the activation of the AMPK pathway.

Esculentoside A; Alcoholic fatty liver disease; Lipid accumulation; Oxidative stress; AMPK pathway

[1] Axley PD, Richardson CT, Singal AK. Epidemiology of alcohol consumption and societal burden of alcoholism and alcoholic liver disease. Clinics in Liver Disease. 2019; 23: 39–50.

[2] Johnston MP, Patel J, Byrne CD. Causes of mortality in non-alcoholic fatty liver disease (NAFLD) and alcohol related fatty liver disease (AFLD). Current Pharmaceutical Design. 2020; 26: 1079–1092.

[3] Koelmel JP, Tan WY, Li Y, Bowden JA, Ahmadireskety A, Patt AC, et al. Lipidomics and redox lipidomics indicate early stage alcohol-induced liver damage. Hepatology Communications. 2022; 6: 513–525.

[4] Ceni E, Mello T, Galli A. Pathogenesis of alcoholic liver disease: role of oxidative metabolism. World Journal of Gastroenterology. 2014; 20: 17756–17772.

[5] Jiang ZB, Gao J, Chai YH, Li W, Luo YF, Chen YZ. Astragaloside alleviates alcoholic fatty liver disease by suppressing oxidative stress. Kaohsiung Journal of Medical Sciences. 2021; 37: 718–729.

[6] Li BY, Li HY, Zhou DD, Huang SY, Luo M, Gan RY, et al. Effects of different green tea extracts on chronic alcohol induced-fatty liver disease by ameliorating oxidative stress and inflammation in mice. Oxidative Medicine and Cellular Longevity. 2021; 2021: 5188205.

[7] Ma Z, Zhang Y, Li Q, Xu M, Bai J, Wu S. Resveratrol improves alcoholic fatty liver disease by downregulating HIF-1alpha expression and mitochondrial ROS production. PLOS ONE. 2017; 12: e0183426.

[8] Han AL. Association of cardiovascular risk factors and metabolic syndrome with non-alcoholic and alcoholic fatty liver disease: a retrospective analysis. BMC Endocrine Disorders. 2021; 21: 91.

[9] Zhu JZ, Yi HW, Huang W, Pang T, Zhou HP, Wu XD. Fatty liver diseases, mechanisms, and potential therapeutic plant medicines. Chinese Journal of Natural Medicines. 2020; 18: 161–168.

[10] Fang C, Pan J, Qu N, Lei Y, Han J, Zhang J, et al. The AMPK pathway in fatty liver disease. Frontiers in Physiology. 2022; 13: 970292.

[11] Lai JR, Hsu YW, Pan TM, Lee CL. Monascin and ankaflavin of monascus purpureus prevent alcoholic liver disease through regulating ampk-mediated lipid metabolism and enhancing both anti-inflammatory and anti-oxidative systems. Molecules. 2021; 26: 6301.

[12] Xiao Q, Zhang S, Yang C, Du R, Zhao J, Li J, et al. Ginsenoside Rg1 ameliorates palmitic acid-induced hepatic steatosis and inflammation in HepG2 cells via the AMPK/NF-kB pathway. International Journal of Endocrinology. 2019; 2019: 7514802.

[13] Yang H, Chen Y, Yu L, Xu Y. Esculentoside A exerts anti-inflammatory activity in microglial cells. International immunopharmacology. 2017; 51: 148–157.

[14] Liu Y, Wei W, Liang S, Fang H, Cao J. Esculentoside A could attenuate apoptosis and inflammation in TNBS-induced ulcerative colitis via inhibiting the nuclear translocation of NF-kB. Annals of Translational Medicine. 2022; 10: 771.

[15] He Z, Zhang H, Li X, Tu S, Wang Z, Han S, et al. The protective effects of Esculentoside A through AMPK in the triple transgenic mouse model of Alzheimer’s disease. Phytomedicine. 2023; 109: 154555.

[16] Wang L, Zhang S, Cheng H, Lv H, Cheng G, Ci X. Nrf2-mediated liver protection by esculentoside A against acetaminophen toxicity through the AMPK/Akt/GSK3β pathway. Free Radical Biology & Medicine. 2016; 101: 401–412.

[17] Zhang F, Wang X, Qiu X, Wang J, Fang H, Wang Z, et al. The protective effect of Esculentoside A on experimental acute liver injury in mice. PLOS ONE. 2014; 9: e113107.

[18] Luo P, Zheng M, Zhang R, Zhang H, Liu Y, Li W, et al. S-Allylmercaptocysteine improves alcoholic liver disease partly through a direct modulation of insulin receptor signaling. Acta Pharmaceutica Sinica B. 2021; 11: 668–679.

[19] Abdelhamid AM, Elsheakh AR, Suddek GM, Abdelaziz RR. Telmisartan alleviates alcohol-induced liver injury by activation of PPAR-γ/Nrf-2 crosstalk in mice. International Immunopharmacology. 2021; 99: 107963.

[20] Jeon S, Carr R. Alcohol effects on hepatic lipid metabolism. Journal of Lipid Research. 2020; 61: 470–479.

[21] Lucey MR. Alcohol-Associated Cirrhosis. Clinics in Liver Disease. 2019; 23: 115–126.

[22] Giannini A, Beamer SE, Butler KA, Magrina J. Diaphragmatic resection and liver mobilization during surgery for advanced ovarian cancer. European Journal of Gynaecological Oncology. 2022; 43: 53–66.

[23] Zhang YC, Lyu ZY, Ma B, Li LM, Wang W, Sheng C, et al. A new risk stratification strategy for fatty liver disease by incorporating MAFLD and fibrosis score in a large US population. Hepatology International. 2022; 16: 835–845.

[24] Kim DH, Kang SH. Implications of a blood sample with an extremely high lipid content in the emergency department: a case report. Signa Vitae. 2022; 18: 163–165.

[25] Cortés O, Fernández J, Boj JR, Canalda C. Effect of formaldehyde on rat liver in doses used in pulpotomies. Journal of Clinical Pediatric Dentistry. 2007; 31: 179–182.

[26] Jia Q, Xia Y, Zhang Q, Wu H, Du H, Liu L, et al. Dietary patterns are associated with prevalence of fatty liver disease in adults. European Journal of Clinical Nutrition. 2015; 69: 914–921.

[27] Mori F, Angelucci C, Cianferoni A, Barni S, Indolfi G, Casini A, et al. Increase of natural killer cells in children with liver transplantation-acquired food allergy. Allergologia Et Immunopathologia. 2018; 46: 447–453.

[28] Zeng MS, Yu WD, Wang HX, Liu JY, Xu PP. A potential antiviral activity of Esculentoside A against binding interactions of SARS-COV-2 spike protein and angiotensin converting enzyme 2 (ACE2). International Journal of Biological Macromolecules. 2021; 183: 2248–2261.

[29] He T, Liu C, Li M, Wang M, Liu N, Zhang D, et al. Integrating non-targeted metabolomics and toxicology networks to study the mechanism of Esculentoside A-induced hepatotoxicity in rats. Journal of Biochemical and Molecular Toxicology. 2021; 35: 1–15.

[30] Chen DZ, Chen LQ, Lin MX, Gong YQ, Ying BY, Wei DZ. Esculentoside A inhibits LPS-induced acute kidney injury by activating PPAR-γ. Microbial Pathogenesis. 2017; 110: 208–213.

[31] Preidis GA, Kim KH, Moore DD. Nutrient-sensing nuclear receptors PPARa and FXR control liver energy balance. The Journal of Clinical Investigation. 2017; 127: 1193–1201.